{"id":"W2747107882","doi":"10.1016/s0140-6736(17)31601-x","title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1239,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Ipilimumab; Medicine; Open label; Oncology; Open label study; Internal medicine; Clinical trial; Adverse effect; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002923225,0.001777201,0.002674768,0.0004119086,0.0004286565,0.001349562,0.001114672,0.001779058,0.005531872],"category_scores_gemma":[0.002062581,0.0007395148,0.002860145,0.0004580567,0.001272285,0.001988207,0.0006215741,0.004953548,0.001188472],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001139574,"about_ca_system_score_gemma":0.0009691077,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001189211,"about_ca_topic_score_gemma":0.002144339,"domain_scores_codex":[0.9990759,0.0005360685,0.0000379372,0.0001378876,0.00005880785,0.0001532732],"domain_scores_gemma":[0.9987746,0.0003798402,0.0002720569,0.0001236943,0.00005010251,0.0003996904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765958,0.003586305,0.0004471255,0.000307265,0.0007412976,0.00002489949,0.00004640583,0.0004295447,0.003127224,0.00005982017,0.0006462756,0.01398805],"study_design_scores_gemma":[0.9162723,0.0773693,0.004092646,0.00002876768,0.0006564988,0.00004182728,0.0000326154,0.0003458104,0.0004257834,0.0001753381,0.0005396291,0.00001950123],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893398,0.004334771,0.0006524941,0.000880776,0.000438254,0.001232495,0.001299859,0.00009417487,0.00172749],"genre_scores_gemma":[0.9886607,0.002213947,0.001514429,0.001321392,0.0004269024,0.001508607,0.001443021,0.00005319637,0.0028579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005531872,"threshold_uncertainty_score":0.01850599,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.133872475199361,"score_gpt":0.4107823894404024,"score_spread":0.2769099142410414,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}